The DOI matches its Crossref record.
The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya
Open accessAbstract
BACKGROUND: Sulphadoxine/sulphalene-pyrimethamine (SP) was adopted in Kenya as first line therapeutic for uncomplicated malaria in 1998. By the second half of 2003, there was convincing evidence that SP was failing and had to be replaced. Despite several descriptive investigations of policy change and implementation when countries moved from chloroquine to SP, the different constraints of moving to artemisinin-based combination therapy (ACT) in Africa are less well documented. METHODS: A narrative description of the process of anti-malarial drug policy change, financing and implementation in Kenya is assembled from discussions with stakeholders, reports, newspaper articles, minutes of meetings and email correspondence between actors in the policy change process. The narrative has been structured to capture the timing of events, the difficulties and hurdles faced and the resolutions reached to the final implementation of a new treatment policy. RESULTS: Following a recognition that SP was failing there was a rapid technical appraisal of available data and replacement options resulting in a decision to adopt artemether-lumefantrine (AL) as the recommended first-line therapy in Kenya, announced in April 2004. Funding requirements were approved by the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) and over 60 million US$ were agreed in principle in July 2004 to procure AL and implement the policy change. AL arrived in Kenya in May 2006, distribution to health facilities began in July 2006 coincidental with cascade in-service training in the revised national guidelines. Both training and drug distribution were almost complete by the end of 2006. The article examines why it took over 32 months from announcing a drug policy change to completing early implementation. Reasons included: lack of clarity on sustainable financing of an expensive therapeutic for a common disease, a delay in release of funding, a lack of comparative efficacy data between AL and amodiaquine-based alternatives, a poor dialogue with pharmaceutical companies with a national interest in antimalarial drug supply versus the single sourcing of AL and complex drug ordering, tendering and procurement procedures. CONCLUSION: Decisions to abandon failing monotherapy in favour of ACT for the treatment of malaria can be achieved relatively quickly. Future policy changes in Africa should be carefully prepared for a myriad of financial, political and legislative issues that might limit the rapid translation of drug policy change into action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya
O'Meara, W. P., Bejon, P., Mwangi, T. W., Okiro, E. A., Peshu, N., Snow, R. W., Newton, C. R., & Marsh, K. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61655-4 · Cited by 446
Self-citationGilson, L., & Raphaely, N. (2008) · Health Policy and Planning · doi:10.1093/heapol/czn019 · Cited by 404
The decline in paediatric malaria admissions on the coast of Kenya
Okiro, E. A., Hay, S. I., Gikandi, P. W., Sharif, S. K., Noor, A. M., Peshu, N., Marsh, K., & Snow, R. W. (2007) · Malaria Journal · doi:10.1186/1475-2875-6-151 · Cited by 254
Self-citationMacharia, P. M., Giorgi, E., Noor, A. M., Waqo, E., Kiptui, R., Okiro, E. A., & Snow, R. W. (2018) · Malaria Journal · doi:10.1186/s12936-018-2489-9 · Cited by 83
Self-citationBorrmann, S., Peto, T., Snow, R. W., Gutteridge, W., & White, N. J. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050227 · Cited by 15
Self-citation
Metadata
- Authors
- Amin, A. A., Zurovac, D., Kangwana, B. B., Greenfield, J., Otieno, D. N., Akhwale, W. S., & Snow, R. W.
- Venue
- Malaria Journal
- Published
- 2007-05-29
- Volume
- 6
- Issue
- 1
- Pages
- 72-72
- ISSN
- 1475-2875 (ISSN-L)
- OpenAlex
- W1984387250
- Cited by
- 174
- References
- 0
- FWCI
- 16.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. https://app.cochat.ai/papers/10.1186/1475-2875-6-72
- The paper
- Amin, A. A., Zurovac, D., Kangwana, B. B., Greenfield, J., Otieno, D. N., Akhwale, W. S., & Snow, R. W. (2007). The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. Malaria Journal. https://doi.org/10.1186/1475-2875-6-72
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.